by Thomas Rønn | Sep 5, 2024 | Press Releases
Purpose Pharma is a patient-centric European based pharmaceutical company focusing on the development and commercialization of novel rare disease and specialty care products in areas of high unmet medical need. Click here to read the Press Release
by Thomas Rønn | Dec 11, 2023 | Press Releases
Hoba Therapeutics, a Novo Holdings founded Danish biotech company dedicated to developing novel therapeutic proteins for patients living with chronic neuropathic pain and hearing loss, today announced that it has raised EUR 23 million (USD 25 million) in a Series A...
by Thomas Rønn | Oct 18, 2023 | Press Releases
Venture forces invest millions in new type of treatment for particularly aggressive form of cancer A syndicate consisting of the Lundbeck Foundation BioCapital, EIR Ventures, EIFO and UCPH Ventures has just made an investment in the Danish biotech company Dania...
by Thomas Rønn | Jul 10, 2023 | Press Releases
Eir Ventures celebrates 3 years anniversary. On July 10, 2020, Eir Ventures I was launched with the announcement of the first close of our fund. Since the launch, Eir Ventures have completed investments in 17 pioneering life science companies; 5 companies have taken...
by Thomas Rønn | Jul 9, 2023 | Press Releases
Eir Ventures welcomes Lovisa Backemar as Principal in the Eir Ventures Team. Lovisa is a Medical Doctor and holds a PhD in clinical epidemiology from the Karolinska Institute. Prior to joining Eir Ventures, Lovisa served as Head of Business Development at the Swedish...
by Thomas Rønn | May 9, 2023 | Press Releases
Eir Ventures are delighted to announce our most recent investment in RAPP. The company was founded in Sweden based on Professor Ulrica Nilsson’s research, offering an evidence-based, interactive, and patient-centric digital platform that addresses several needs in the...
by Thomas Rønn | Apr 11, 2023 | Press Releases
Eir Ventures are delighted to announce our most recent investment in GutCRINE. The company is a pioneering spin out from Copenhagen University developing a new first in class therapy targeting metabolic and age-related diseases like obesity, type 2 diabetes,...
by Thomas Rønn | Oct 25, 2022 | Press Releases
Henlez mission is to transform the management of skin conditions by using enzymes. Henlez’s pre-clinical lead development program, HEN-001, is an enzyme-based, topical application directed towards hidradenitis suppurativa (HS) – a highly stigmatizing and chronic...
by Thomas Rønn | Sep 14, 2022 | Press Releases
Pretzel is developing treatments to address the genetic roots of mitochondrial dysfunction. Pretzel was founded by some of the world’s foremost academics in mitochondrial biology, and we benefit from the leadership of accomplished experts in drug discovery, drug...
Recent Comments